Axsome Therapeutics (AXSM) Amortization of Deferred Charges (2015 - 2017)
Axsome Therapeutics recorded quarterly Amortization of Deferred Charges of $85628.0 in Q4 2017, down 2.78% quarter-over-quarter from $88074.0 in Q3 2017.
Axsome Therapeutics' Amortization of Deferred Charges history runs 2 years deep, the most recent figure standing at $85628.0 for Q4 2017.
- In Q4 2017, Amortization of Deferred Charges changed N/A year-over-year to $85628.0; the TTM figure through Dec 2017 stood at $346978.0 (changed N/A YoY), while the FY2017 annual figure was $346978.0, up 597.01% from the prior year.
- Amortization of Deferred Charges came in at $85628.0 for Q4 2017 at Axsome Therapeutics, down from $88074.0 in the prior quarter.
- In the past five years, Amortization of Deferred Charges ranged from a high of $88074.0 in Q3 2017 to a low of $1806.0 in Q1 2015.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Axsome Therapeutics | 11.82 Bn | 11.51 Bn | 176.48 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2017 | 85,628.00 |
| Dec 31, 2017 | 85,628.00 |
| Sep 30, 2017 | 88,074.00 |
| Sep 30, 2017 | 88,074.00 |
| Jun 30, 2017 | 87,117.00 |
| Jun 30, 2017 | 87,117.00 |
| Mar 31, 2017 | 86,159.00 |
| Mar 31, 2017 | 86,159.00 |
| Sep 30, 2015 | 2,235.00 |
| Sep 30, 2015 | 2,235.00 |
| Jun 30, 2015 | 3,716.00 |
| Jun 30, 2015 | 3,716.00 |
| Mar 31, 2015 | 1,806.00 |
| Mar 31, 2015 | 1,806.00 |